From October 13 to 15, JSC Grindeks will participate in the international exhibition „CPhI Worldwide 2009″ in Feria de Madrid, Spain. During exhibition Grindeks will introduce visitors to its world class services and solutions in research, development, manufacturing, registration and sale of active pharmaceutical ingredients (API) and final dosage forms (FDF). Grindeks exhibition stand will be placed in the Hall 10 with number 10G41.
Chairman of the board of JSC Grindeks, Jānis Romanovskis, admits: “Grindeks has all the necessary resources to offer creative and farsighted business solutions for still very reasonable prices – advantageous geographical location, close traditional scientific and industrial ties between Latvia and Russia and other CIS and Eastern countries, European business culture, language skills, international quality standards and strong scientific resources. Participation in “CPhI 2008″ last year proved that we can successfully compete on the global pharmacy market as a stable and reliable partner whose products and services are relevant to the highest quality requirements. We are certain that participation in the exhibition offers excellent possibility to generate new business alliances, renew existing partnerships, expose new innovations and strengthen the network of a company”.
In its exhibition stand Grindeks will promote cooperation in three main business fields:
Research, development, manufacturing and sales of API.
Grindeks ensures research and development of API in compliance with cGMP standards and suggests solutions meeting the specific client demands. The advanced analytical scale-up laboratory not only provides new opportunities for researching new products, but also allows manufacturing of products in small batches. Grindeks offers complicated, multi-stage synthesis (5-10 stage) of APIs particularly for niche pharmaceutical products utilising world class technology and at a reasonable price. API manufacturing facilities ensure bulk production of substances and intermediary products as well as products scaling.
Development and manufacturing of FDF.
Grindeks offers full service of contract-manufacturing of FDF – development of activities in performing FDF, validation of the manufacturing process and analysis methods, development of drug registration documentation and manufacturing of different technologies of FDF – tablets, capsules and syrups. Manufacturing is organized in brand new world-level pharmaceutical plant with an annual capacity of 1.5 billion tablets and 500 million capsules. The manufacturing processes at the plant are managed in accordance with GMP and ISO quality standards, a D class cleanliness level is maintained and modern, high capacity machines are installed.
Registration and marketing services.
Grindeks has a wide sales network and great experience in the market as well as all resources necessary to provide contract registration services to meet the clients demands. Offered services include out-licensing, regulatory submissions, marketing authorization, translation, liaison, consulting, readability tests, as well as entire development of drug registration documents in CTD, eCTD in compliance with the EU and CIS countries requirements. Due to its long-term presence in the markets of Russia and other CIS countries, Grindeks has deep knowledge of these markets and legislation and can offer liaison with Russia, Ukraine, Belarus and other CIS countries regulatory authorities, product registration, marketing and sales in these markets.
„CPhIWorldwide” the world’s leading exhibition which gathers everyone from manufacturers and purchasers of fine chemicals and pharmaceuticals to solution providers, all in search of the latest industry developments. This year approximately 1000 companies from 125 countries will participate.
Grindeks participation in the exhibition is co financed by ERDF.
About Grindeks
Grindeks is the leading pharmaceutical company in the Baltic States. The main directions of its operation are research, development, manufacturing and sales of original products, as well as generics and active pharmaceutical ingredients. «Grindeks» specializes in the heart and cardiovascular, psychotropic and anti-cancer therapeutic groups of medications.
Grindeks concern consists of four subsidiary companies in Latvia, Estonia and Russia; as well as representatives and representative offices in 14 countries. Products of the company are exported to more than 40 countries and its export comprises more than 96% of the total turnover. The main markets are the Baltic States, Russia and other CIS countries, as well as Japan and USA. The shares of JSC Grindeks are listed in the Official List of „Nasdaq OMX Riga”.
Further information
Laila Kļaviņa
Head of the Communications Department
JSC Grindeks
E-mail: [email protected]
Phones: +371 67083370, +371 29256012
